ID   NHRF3_MOUSE             Reviewed;         519 AA.
AC   Q9JIL4; Q8CDP5; Q8R4G2; Q9CQ72;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   22-JUL-2015, entry version 124.
DE   RecName: Full=Na(+)/H(+) exchange regulatory cofactor NHE-RF3;
DE            Short=NHERF-3;
DE   AltName: Full=CFTR-associated protein of 70 kDa;
DE   AltName: Full=Na(+)/H(+) exchanger regulatory factor 3;
DE   AltName: Full=Na/Pi cotransporter C-terminal-associated protein 1;
DE            Short=NaPi-Cap1;
DE   AltName: Full=PDZ domain-containing protein 1;
DE   AltName: Full=Sodium-hydrogen exchanger regulatory factor 3;
GN   Name=Pdzk1; Synonyms=Cap70, Nherf3;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 351-376 AND 467-485,
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INTERACTION
RP   WITH CFTR.
RX   PubMed=11051556; DOI=10.1016/S0092-8674(00)00096-9;
RA   Wang S., Yue H., Derin R.B., Guggino W.B., Li M.;
RT   "Accessory protein facilitated CFTR-CFTR interaction, a molecular
RT   mechanism to potentiate the chloride channel activity.";
RL   Cell 103:169-179(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12556478; DOI=10.1128/MCB.23.4.1175-1180.2003;
RA   Kocher O., Pal R., Roberts M., Cirovic C., Gilchrist A.;
RT   "Targeted disruption of the PDZK1 gene by homologous recombination.";
RL   Mol. Cell. Biol. 23:1175-1180(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Testis;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SLC17A1.
RX   PubMed=11099500; DOI=10.1074/jbc.M008745200;
RA   Gisler S.M., Stagljar I., Traebert M., Bacic D., Biber J., Murer H.;
RT   "Interaction of the type IIa Na/Pi-cotransporter with PDZ proteins.";
RL   J. Biol. Chem. 276:9206-9213(2001).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH AKAP2; SLC22A12; SLC22A4; SLC26A6;
RP   SLC9A3R1; SLC9A3R2 AND PDZK1IP1.
RX   PubMed=14531806; DOI=10.1046/j.1523-1755.2003.00266.x;
RA   Gisler S.M., Pribanic S., Bacic D., Forrer P., Gantenbein A.,
RA   Sabourin L.A., Tsuji A., Zhao Z.-S., Manser E., Biber J., Murer H.;
RT   "PDZK1: I. a major scaffolder in brush borders of proximal tubular
RT   cells.";
RL   Kidney Int. 64:1733-1745(2003).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH SLC22A5.
RX   PubMed=15523054; DOI=10.1124/mol.104.002212;
RA   Kato Y., Sai Y., Yoshida K., Watanabe C., Hirata T., Tsuji A.;
RT   "PDZK1 directly regulates the function of organic cation/carnitine
RT   transporter OCTN2.";
RL   Mol. Pharmacol. 67:734-743(2005).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16141316; DOI=10.1073/pnas.0506578102;
RA   Thomson R.B., Wang T., Thomson B.R., Tarrats L., Girardi A.,
RA   Mentone S., Soleimani M., Kocher O., Aronson P.S.;
RT   "Role of PDZK1 in membrane expression of renal brush border ion
RT   exchangers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13331-13336(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-488; SER-489; SER-492
RP   AND SER-514, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [10]
RP   STRUCTURE BY NMR OF 242-331.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the third PDZ domain of PDZ domain containing
RT   protein 1.";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 7-106, INTERACTION WITH
RP   SCARB1, FUNCTION, AND MUTAGENESIS OF LYS-14 AND TYR-20.
RX   PubMed=20739281; DOI=10.1074/jbc.M110.164418;
RA   Kocher O., Birrane G., Tsukamoto K., Fenske S., Yesilaltay A., Pal R.,
RA   Daniels K., Ladias J.A., Krieger M.;
RT   "In vitro and in vivo analysis of the binding of the C terminus of the
RT   HDL receptor scavenger receptor class B, type I (SR-BI), to the PDZ1
RT   domain of its adaptor protein PDZK1.";
RL   J. Biol. Chem. 285:34999-35010(2010).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.30 ANGSTROMS) OF 238-323 IN COMPLEX WITH
RP   SCARB1, INTERACTION WITH SCARB1, MUTAGENESIS OF TYR-20 AND TYR-253,
RP   AND FUNCTION.
RX   PubMed=21602281; DOI=10.1074/jbc.M111.242362;
RA   Kocher O., Birrane G., Yesilaltay A., Shechter S., Pal R., Daniels K.,
RA   Krieger M.;
RT   "Identification of the PDZ3 domain of the adaptor protein PDZK1 as a
RT   second, physiologically functional binding site for the C terminus of
RT   the high density lipoprotein receptor scavenger receptor class B type
RT   I.";
RL   J. Biol. Chem. 286:25171-25186(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 7-106 IN COMPLEX WITH PTGIR,
RP   AND INTERACTION WITH PTGIR.
RX   PubMed=23457445; DOI=10.1371/journal.pone.0053819;
RA   Birrane G., Mulvaney E.P., Pal R., Kinsella B.T., Kocher O.;
RT   "Molecular analysis of the prostacyclin receptor's interaction with
RT   the PDZ1 domain of its adaptor protein PDZK1.";
RL   PLoS ONE 8:E53819-E53819(2013).
CC   -!- FUNCTION: A scaffold protein that connects plasma membrane
CC       proteins and regulatory components, regulating their surface
CC       expression in epithelial cells apical domains. May be involved in
CC       the coordination of a diverse range of regulatory processes for
CC       ion transport and second messenger cascades. In complex with
CC       SLC9A3R1, may cluster proteins that are functionally dependent in
CC       a mutual fashion and modulate the trafficking and the activity of
CC       the associated membrane proteins. May play a role in the cellular
CC       mechanisms associated with multidrug resistance through its
CC       interaction with ABCC2 and PDZK1IP1. May potentiate the CFTR
CC       chloride channel activity (By similarity). Required for normal
CC       cell-surface expression of SCARB1. Plays a role in maintaining
CC       normal plasma cholesterol levels via its effects on SCARB1. Plays
CC       a role in the normal localization and function of the chloride-
CC       anion exchanger SLC26A6 to the plasma membrane in the brush border
CC       of the proximal tubule of the kidney. May be involved in the
CC       regulation of proximal tubular Na(+)-dependent inorganic phosphate
CC       cotransport therefore playing an important role in tubule
CC       function. {ECO:0000250, ECO:0000269|PubMed:11051556,
CC       ECO:0000269|PubMed:12556478, ECO:0000269|PubMed:14531806,
CC       ECO:0000269|PubMed:15523054, ECO:0000269|PubMed:16141316,
CC       ECO:0000269|PubMed:20739281, ECO:0000269|PubMed:21602281}.
CC   -!- SUBUNIT: Interacts with PDZK1IP1 and ABCC2. Binds to the C-
CC       terminal region of SLC26A3. Interacts (via C-terminal PDZ domain)
CC       with SLC26A6 (via C-terminal domain). Interacts (via C-terminal
CC       PDZ domain) with SLC9A3 (via C-terminal domain) (By similarity).
CC       Component of a complex, composed of PDZK1, SYNGAP1, KLHL17 and
CC       NMDA receptors. Interacts (via PDZ1 domain) directly with KLHL17;
CC       the interaction is important for integrity of actin cytoskeleton
CC       structures in neurons (By similarity). Forms a heterodimeric
CC       complex with SLC9A3R1. Interacts with AKAP2, BCR, CFTR, SLCO1A1,
CC       SLC22A12, SLC22A4, SLC22A5, SLC26A6, SLC9A3R2 and SLC17A1.
CC       Interacts (via the first PDZ domain) with PTGIR (via non-
CC       isoprenylated C-terminus). Interacts (via PDZ domains 1 and 3)
CC       with SCARB1 (C-terminal domain). {ECO:0000250,
CC       ECO:0000269|PubMed:11051556, ECO:0000269|PubMed:11099500,
CC       ECO:0000269|PubMed:14531806, ECO:0000269|PubMed:15523054,
CC       ECO:0000269|PubMed:20739281, ECO:0000269|PubMed:21602281,
CC       ECO:0000269|PubMed:23457445}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane
CC       protein. Cell membrane. Note=Localized in the brush border
CC       membrane of renal proximal tubule cells. Associated with
CC       peripheral membranes. Localizes to the apical compartment of
CC       proximal cells and to sinusoidal liver membranes.
CC   -!- TISSUE SPECIFICITY: Expressed in kidney, liver, small intestine.
CC       brain, lung, and testis (at protein level).
CC       {ECO:0000269|PubMed:11051556, ECO:0000269|PubMed:12556478}.
CC   -!- DOMAIN: The PDZ 2 and 3 domains seem to be involved in the
CC       interaction with SLC26A3. {ECO:0000250}.
CC   -!- DOMAIN: Interaction with the C-terminus of CFTR could be mediated
CC       through independent binding of PDZ 1, 3 and 4 domains.
CC   -!- DOMAIN: The PDZ 1 and 3 domains seem to be involved in the
CC       interaction with SLCO1A1. {ECO:0000250}.
CC   -!- DOMAIN: The PDZ 1 domain interacts with BCR. {ECO:0000250}.
CC   -!- DOMAIN: The PDZ 2 and 4 domains do not interact with the C-
CC       terminal region of SCARB1.
CC   -!- MISCELLANEOUS: Disruption of the gene was not associated with
CC       abnormal growth and development or redistribution of interacting
CC       proteins. However, a modulation of expression of selective ion
CC       channels in the kidney, as well as increased serum cholesterol
CC       levels were observed.
CC   -!- SIMILARITY: Belongs to the NHER family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 4 PDZ (DHR) domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00143}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL84634.1; Type=Frameshift; Positions=229, 261; Evidence={ECO:0000305};
CC       Sequence=BAC26605.1; Type=Frameshift; Positions=519; Note=The frameshift causes a read through of the stop codon.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF474247; AAL84634.1; ALT_FRAME; mRNA.
DR   EMBL; AF220100; AAF73863.1; -; mRNA.
DR   EMBL; AK006269; BAB24493.1; -; mRNA.
DR   EMBL; AK029752; BAC26598.1; -; mRNA.
DR   EMBL; AK029764; BAC26605.1; ALT_FRAME; mRNA.
DR   EMBL; AK012070; BAB28007.1; -; mRNA.
DR   EMBL; AK014879; BAB29600.1; -; mRNA.
DR   EMBL; BC013512; AAH13512.1; -; mRNA.
DR   CCDS; CCDS17649.1; -.
DR   RefSeq; NP_001139473.1; NM_001146001.1.
DR   RefSeq; NP_067492.2; NM_021517.2.
DR   RefSeq; XP_006501896.1; XM_006501833.1.
DR   RefSeq; XP_011238480.1; XM_011240178.1.
DR   UniGene; Mm.489677; -.
DR   PDB; 2D90; NMR; -; A=242-330.
DR   PDB; 2EDZ; NMR; -; A=1-107.
DR   PDB; 3NGH; X-ray; 1.80 A; A/B=7-106.
DR   PDB; 3R68; X-ray; 1.30 A; A=238-323.
DR   PDB; 3R69; X-ray; 1.50 A; A/B=241-322.
DR   PDB; 4F8K; X-ray; 1.70 A; A/B=7-106.
DR   PDBsum; 2D90; -.
DR   PDBsum; 2EDZ; -.
DR   PDBsum; 3NGH; -.
DR   PDBsum; 3R68; -.
DR   PDBsum; 3R69; -.
DR   PDBsum; 4F8K; -.
DR   ProteinModelPortal; Q9JIL4; -.
DR   SMR; Q9JIL4; 1-107, 132-492.
DR   BioGrid; 208488; 2.
DR   IntAct; Q9JIL4; 6.
DR   MINT; MINT-148595; -.
DR   STRING; 10090.ENSMUSP00000058936; -.
DR   PhosphoSite; Q9JIL4; -.
DR   MaxQB; Q9JIL4; -.
DR   PaxDb; Q9JIL4; -.
DR   PRIDE; Q9JIL4; -.
DR   GeneID; 59020; -.
DR   KEGG; mmu:59020; -.
DR   UCSC; uc008qoi.2; mouse.
DR   CTD; 5174; -.
DR   MGI; MGI:1928901; Pdzk1.
DR   eggNOG; NOG315208; -.
DR   HOGENOM; HOG000113782; -.
DR   HOVERGEN; HBG082115; -.
DR   InParanoid; Q9JIL4; -.
DR   PhylomeDB; Q9JIL4; -.
DR   TreeFam; TF350449; -.
DR   EvolutionaryTrace; Q9JIL4; -.
DR   NextBio; 314580; -.
DR   PRO; PR:Q9JIL4; -.
DR   Proteomes; UP000000589; Unplaced.
DR   Bgee; Q9JIL4; -.
DR   CleanEx; MM_PDZK1; -.
DR   ExpressionAtlas; Q9JIL4; baseline and differential.
DR   Genevisible; Q9JIL4; MM.
DR   GO; GO:0031526; C:brush border membrane; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; ISO:MGI.
DR   GO; GO:0015879; P:carnitine transport; ISO:MGI.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0034767; P:positive regulation of ion transmembrane transport; ISO:MGI.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IMP:UniProtKB.
DR   GO; GO:0044070; P:regulation of anion transport; IMP:UniProtKB.
DR   GO; GO:0006810; P:transport; ISO:MGI.
DR   Gene3D; 2.30.42.10; -; 4.
DR   InterPro; IPR001478; PDZ.
DR   Pfam; PF00595; PDZ; 4.
DR   SMART; SM00228; PDZ; 4.
DR   SUPFAM; SSF50156; SSF50156; 4.
DR   PROSITE; PS50106; PDZ; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Membrane; Phosphoprotein;
KW   Reference proteome; Repeat.
FT   CHAIN         1    519       Na(+)/H(+) exchange regulatory cofactor
FT                                NHE-RF3.
FT                                /FTId=PRO_0000058288.
FT   DOMAIN        9     90       PDZ 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN      128    215       PDZ 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN      243    323       PDZ 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   DOMAIN      378    458       PDZ 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00143}.
FT   MOD_RES     148    148       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5T2W1}.
FT   MOD_RES     488    488       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17242355}.
FT   MOD_RES     489    489       Phosphoserine.
FT                                {ECO:0000269|PubMed:17242355}.
FT   MOD_RES     492    492       Phosphoserine.
FT                                {ECO:0000269|PubMed:17242355}.
FT   MOD_RES     514    514       Phosphoserine.
FT                                {ECO:0000269|PubMed:17242355}.
FT   MUTAGEN      14     14       K->A: Impairs interaction of the first
FT                                PDZ domain with SCARB1.
FT                                {ECO:0000269|PubMed:20739281}.
FT   MUTAGEN      20     20       Y->A: Disrupts interaction of the first
FT                                PDZ domain with SCARB1. Abolishes
FT                                interaction with SCARB1; when associated
FT                                with A-253. {ECO:0000269|PubMed:20739281,
FT                                ECO:0000269|PubMed:21602281}.
FT   MUTAGEN     253    253       Y->A: Disrupts interaction of the third
FT                                PDZ domain with SCARB1. Abolishes
FT                                interaction with SCARB1; when associated
FT                                with A-20. {ECO:0000269|PubMed:21602281}.
FT   CONFLICT     24     24       L -> R (in Ref. 1; AAL84634).
FT                                {ECO:0000305}.
FT   CONFLICT    135    135       L -> S (in Ref. 1; AAL84634).
FT                                {ECO:0000305}.
FT   CONFLICT    162    162       D -> N (in Ref. 3; BAB24493/BAC26598/
FT                                BAC26605/BAB28007/BAB29600).
FT                                {ECO:0000305}.
FT   CONFLICT    162    162       D -> S (in Ref. 1; AAL84634).
FT                                {ECO:0000305}.
FT   STRAND        8     13       {ECO:0000244|PDB:4F8K}.
FT   STRAND       23     25       {ECO:0000244|PDB:4F8K}.
FT   STRAND       34     36       {ECO:0000244|PDB:4F8K}.
FT   HELIX        43     46       {ECO:0000244|PDB:4F8K}.
FT   STRAND       54     58       {ECO:0000244|PDB:4F8K}.
FT   STRAND       64     66       {ECO:0000244|PDB:2EDZ}.
FT   HELIX        68     77       {ECO:0000244|PDB:4F8K}.
FT   TURN         78     80       {ECO:0000244|PDB:4F8K}.
FT   STRAND       81     87       {ECO:0000244|PDB:4F8K}.
FT   HELIX        89     97       {ECO:0000244|PDB:4F8K}.
FT   HELIX       102    104       {ECO:0000244|PDB:4F8K}.
FT   STRAND      242    247       {ECO:0000244|PDB:3R68}.
FT   STRAND      252    254       {ECO:0000244|PDB:3R69}.
FT   STRAND      256    259       {ECO:0000244|PDB:3R68}.
FT   STRAND      265    269       {ECO:0000244|PDB:3R68}.
FT   HELIX       276    280       {ECO:0000244|PDB:3R68}.
FT   STRAND      286    291       {ECO:0000244|PDB:3R68}.
FT   HELIX       301    309       {ECO:0000244|PDB:3R68}.
FT   TURN        310    313       {ECO:0000244|PDB:3R68}.
FT   STRAND      314    321       {ECO:0000244|PDB:3R68}.
SQ   SEQUENCE   519 AA;  56499 MW;  681B57F4E237BC28 CRC64;
     MASTFNPREC KLSKQEGQNY GFFLRIEKDT DGHLIRVIEE GSPAEKAGLL DGDRVLRING
     VFVDKEEHAQ VVELVRKSGN SVTLLVLDGD SYEKAVKNQV DLKELDQSQR EAALNDKKPG
     PGMNGAVEPC AQPRLCYLVK EGNSFGFSLK TIQGKKGVYL TDIMPQGVAM KAGVLADDHL
     IEVNGENVEN ASHEEVVEKV TKSGSRIMFL LVDKETARCH SEQKTQFKRE TASLKLLPHQ
     PRVVVIKKGS NGYGFYLRAG PEQKGQIIKD IEPGSPAEAA GLKNNDLVVA VNGKSVEALD
     HDGVVEMIRK GGDQTTLLVL DKEAESIYSL ARFSPLLYCQ SQELPNGSVK EGPAPIPAPL
     EATGSEPTED AEGHKPKLCR LLKEDDSYGF HLNAIRGQPG SFVKEVQQGG PADKAGLENE
     DVIIEVNGEN VQEEPYDRVV ERIKSSGKHV TLLVCGKMAY SYFQAKKIPI VSSMAEPLVA
     GPDEKGETSA ESEHDAHPAK DRTLSTASHS SSNSEDTEM
//
